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SELECTION OF THE MONTH 
Big Titles: New treatment strategies in hepatitis B: targeting TLR7, HBV gene 
expression, and cytoplasmatic nucleocapsid transport  
Alcohol abuse in adolescence predicts future Cirrhosis 
 
Small Titles:  
Alcohol intake in early life and risk of severe liver disease 
Unravelling mechanisms of NK cell activation 
A new score to allow usage of livers from deceased donors 
 
LIVER FIBROSIS 
G proteins meets autophagy 
Hepatic stellate cells (HSCs) play a central role in the development of liver fibrosis. 
The microenvironment of these cells exhibits elevated levels of signals whose cognate 
cell surface receptors are guanine nucleotide-binding (G)-protein-coupled receptors. 
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These receptors can use a G protein called guanine nucleotide-binding protein subunit 
alpha-12 (Gα12) to transduce the extracellular signal brought by the agonist. Because 
little is known about the effect of Gα12-mediated signal transduction on HSC, this 
question was addressed by Kim et al. in elegant mouse models. They found that MiR-
16 dysregulation in HSCs causes Gα12 overexpression, which activates HSCs 
by facilitating autophagy through the conjugation of ubiquitin-like protein 
ATG12 (encoded by Atg12) with autophagy protein 5 (encoded by Atg5). The 
authors speculate that Gα12 and the regulatory molecules may serve targets in the 
amelioration of liver fibrosis. 
 
ALCOHOLIC LIVER DISEASE 
Alcohol consumption in early life predicts severe alcohol disease and 
performance of scoring systems in alcoholic hepatitis 
Excessive alcohol consumption in young people is a major public health problem 
worldwide. Whether alcohol consumption early in life is associated with later 
development of severe liver disease is uncertain. In this issue of the Journal, Hagström 
et al. used data on alcohol consumption at conscription to military service from 43,296 
men (18-20 years) in Sweden during the late 60s. During a mean follow-up of 38 years, 
383 men developed severe liver disease. Alcohol consumption in people 18-20-
year-old was associated with an increased risk of development of severe liver 
disease in a dose-response pattern. This important study highlights that alcohol 
consumption in young men is associated with an increased risk for severe liver 
disease. The risk was dose-dependent, with no sign of a threshold effect. Current 
guidelines for safe alcohol intake in men might have to be revised, and more effective 
campaigns aimed at preventing excessive alcohol consumption among young people 
should be launched. In another article in this issue, Forrest et al. studied the 
performance of several existing scoring systems in predicting survival in alcoholic 
hepatitis (AH), the most severe form of alcoholic liver disease. Using the large cohort 
from the STOPAH trial (1,068 patients), the authors compared ‘static’ scores at 
admission including Maddrey’s discriminant function (DF), MELD, ABIC and Glasgow 
(GASH). Also, the performance of the “dynamic” scores at 7 days including the Lille 
score were evaluated. The area under the curve for the Maddrey’s DF was 0.670, 
significantly lower than for MELD, ABIC and GAHS at 0.704, 0.726 and 0.713 
respectively. 'Dynamic' scores and change in 'static' score by Day 7 had similar 
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performances. In patients with high 'static' scores without gastro-intestinal bleeding or 
sepsis, prednisolone reduced 28-day mortality. Overall mortality from treating all 
patients with a DF ≥ 32 and Lille assessment (90-day mortality 26.8%) was greater 
than combining newer 'static' and 'dynamic' scores. The authors conclude that 
MELD, ABIC and GAHS are better prognostic scores than the DF. Low scores 
have a favorable outcome not improved with prednisolone. Importantly, combined 
baseline 'static' and Day 7 scores reduce the number of patients exposed to 
corticosteroids and improve 90-day outcome.  
 
HEPATITIS B VIRUS (HBV) INFECTION 
An oral TLR 7 agonist in phase II, a novel HBV expression inhibitor, targeting the 
cytoplasmatic HBV nucleocapsid transport 
The innate immunity plays a crucial role in controlling HBV infection and has become 
an attractive target for future HBV drug development. Vesatolimod (GS-9620), a 
selective and potent oral agonist of Toll-like receptor 7 (TLR7), an activator of innate 
and adaptive immune responses, has shown significant reductions in HBV DNA and 
HBsAg levels in chronically infected chimpanzees and woodchucks. This report by 
Janssen et al. summarizes the first of two phase 2 clinical trials to examine the efficacy 
and safety of vesatolimod in patients with chronic HBV infection who were virally 
suppressed on oral antiviral treatment. Despite demonstrating a vesatolimod dose-
dependent and transient induction of ubiquitin-like protein ISG15 (also known 
as Interferon-induced 15 kDa protein), no significant declines in hepatitis B 
surface antigen levels were observed. An ongoing phase 2 study now examines the 
efficacy and safety of vesatolimod in treatment-naïve and viremic patients with chronic 
hepatitis B (NCT02579382). 
High levels of viral antigens such as HBsAg may contribute to the exhaustion of innate 
and adaptive immune function seen in patients with chronic hepatitis B. Several lines 
of evidence suggest a potential therapeutic role for antiviral agents that reduce HBsAg 
levels hereby restoring virus-specific immune responsiveness. The antiviral properties 
of RG7834, an orally available small molecule HBV expression inhibitor, were 
evaluated by Mueller et al. in natural HBV infection assays as well as in HBV-infected 
humanized mouse model either alone or in combination with entecavir. RG7834 led to 
a fast and selective reduction in HBV mRNAs hereby leading to a significant 
reduction in both levels of HBV DNA and viral proteins including HBsAg. Further 
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studies are needed to see whether reduction of the intracellular and circulating HBsAg 
may also lead to a reversal of antiviral immunity as a novel therapeutic approach.  
The mechanisms involved in transporting the HBV nucleocapsid to the nuclear pore 
for delivery into the nucleus and release of the viral genome are poorly understood. In 
an elegant study, Osseman et al. identified a chaperone called dynein light chain 
1, cytoplasmic (encoded by DYNLL1) as the major functional binding partner 
needed for the cytoplasmic transport of mature, viral genome containing, HBV 
nucleocapsids to the nucleus, hence describing for the first time the evidence of 
a viral cargo. Targeting the HBV nucleocapsid transport by inhibiting the capsid-
dynein LL1 interaction may become a fascinating approach to inhibit new hepatocyte 
infections but also to increase elimination of already infected hepatocytes.  
 
HEPATITIS C VIRUS (HCV) INFECTION 
How alcohol-use disorders drive HCV disease, treatment as prevention, 
unravelling mechanisms of NK cell activation 
The course of chronic HCV infection can be highly variable and certain cofactors like 
age and chronic alcohol-use contribute to the individual rate of disease progression ( 
to cirrhosis). To figure out the relative contribution of alcohol-use disorders to HCV-
related decompensated cirrhosis development, Alavi et al. performed a large 
population-based study including nearly 175,000 HCV-infected patients in British 
Columbia, Canada, New South Wales, Australia, and Scotland. Among the 7,233 
patients with decompensated cirrhosis diagnosis 28%-50% had an alcohol-use 
disorder. The alcohol-use disorder-associated population attributable fractions 
of decompensated cirrhosis related to alcohol-use disorders were 13%, 25%, 
and 40% in Canada, Australia, and Scotland, respectively. Authors made the point 
that continued heavy alcohol intake is likely to impact potential benefits of direct-acting 
antivirals (DAAs)-based cure on individual-level liver disease progression and 
population-level liver disease burden, and action against alcohol-use disorders should 
form a strong component of HCV public health strategies. 
Preventing HCV transmission among people who inject drugs (PWID) is critical to limit 
future liver disease burden worldwide. The arrival of highly effective and short duration 
DAAs with cure rates above 95% has made HCV “treatment as prevention” more than 
a theoretical possibility. In this issue of the Journal, Fraser et al. estimated the current 
HCV treatment rates and coverage of opioid substitution therapy (OST) and needle 
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and syringe programs (NSP) in PWID across 11 different sites in Europe, and 
assessed the impact of scaled-up HCV treatment rates and other primary preventions 
on the HCV prevalence and incidence over the next ten years. The projected HCV 
prevalence in PWID in 2016 varied from <25% to > 55% according to the different 
countries but only <2%-5% of those being chronically infected were treated annually. 
The authors clearly show that treatment scale-up is needed to achieve 
observable reductions in chronic HCV prevalence among PWID in most sites in 
Europe. 
Natural killer (NK) cells comprise 30% of liver lymphocytes, a percentage that can 
increase up to 80% in HCV-infected patients, and exert their anti-viral effector function 
primarily by the production of IFN-γ that directly suppresses HCV replication. The aim 
of the remarkable study by Cerwenka et al. was to dissect mechanisms leading to NK 
cell activation and proliferation in response to HCV. Main findings were that NK cells 
become activated and proliferate when they are co-cultured with HCV-containing 
liver cells, highlighting to a novel cell-cell-mediated pathway of the interplay 
between infected hepatocytes, monocytes and NK cells to achieve NK cell anti-
viral functionality. The data further imply the cell surface molecule OX40 and OX40L 
axis as an important activation module in the cross-talk between NK cells and 
monocyte-derived cells/HCV-infected hepatocytes that might play an important role not 
only in HCV but also in other viral infections. 
 
LIVER TRANSPLANTATION 
Development and validation of the UK-DCD-Risk score to select livers from 
deceased donors (DCD) for transplantation 
Organ shortages lead to the death of substantial number of patients with advanced 
liver disease. One of the strategies to increase the number of organs available for 
transplantation is to use organs from deceased donors. Many observational studies 
have shown that selection of DCD organs is the key to using them successfully. 
Schlegel et al. have developed and validated, for the first time, a new score, the 
UK-DCD-Risk score, which includes clinical and easily obtained donor and 
recipient factors that can be used to select organs and suitable recipients for 
transplantation. With further validation, this scoring system can allow better usage of 
organs that are often discarded or used inappropriately and change clinical practice. 
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ACUTE ON CHRONIC LIVER FAILURE (ACLF) IN CHILDREN 
Validation of the CLIF scores a prognostic tool for pediatric patients with ACLF  
ACLF is a devastating syndrome that occurs in cirrhotic patients and is characterized 
by organ failures and high risk of short-term mortality. The available data in adults have 
shown that this syndrome is distinct to acute decompensation and can be diagnosed 
using an organ failure scoring system but whether this is true in children has thus far 
been unknown. Bolia et al. studied cirrhotic children with acute decompensation 
and developed a new score, with high sensitivity and specificity, the pediatric 
CLIF-SOFA score to identify patients at high risk of short-term mortality. In 
addition to organ failures, they identified serum sodium as an independent predictor of 
mortality. This important study, with further validation will allow better characterization 
of ACLF in children. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Leveraging ARID1A deficiency, statin therapy for HCC prevention,  
AT-rich interactive domain-containing protein 1A (also known as BAF250; encoded by 
ARID1A) is a component of the ATP-dependent chromatin-remodeling complex, which 
may act as a tumor suppressor gene. ARID1A is frequently mutated in HCC. However, 
it remains unknown how the ARID1A–encoded protein suppresses HCC development 
and whether ARID1A deficiency could be exploited for therapy. These questions were 
addressed by Hu et al., mainly by using mouse models of HCC and cell lines. Their 
results reveal that Arid1a-deficiency activates angiopoietin 2-dependent 
angiogenesis and promotes HCC progression. Interestingly, loss of Arid1a in HCCs 
confers sensitivity to angiopoietin 2 blockade and sorafenib treatment. 
That statin therapy prevents HCC development in individuals at risk of this cancer is 
unknown. Kim et al. conducted a nationwide, nested case-control study using data 
from the National Health Insurance Service Physical Health Examination Cohort 2002-
2013 in the Republic of Korea with the aim to investigate the risk of HCC after statin 
use in the whole general population and evaluated the effects of preexisting diabetes 
and cirrhosis on that risk. A total of 1,642 HCC cases were matched to 8,210 control 
individuals from 514,866 participants. They found that the adjusted odds ratio (OR) for 
HCC was 0.44 (95% confidence interval [CI], 0.33 to 0.58), in statin users vs. non-
users. Moreover, among patients with diabetes, the adjusted OR for HCC was 0.28 
(95% CI, 0.17 to 0.46), in users vs. non-users. Among patients with cirrhosis the 
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adjusted OR was 0.39 (95% CI=0.26-0.60), in users vs. non-users. Therefore, statin 
use may have a beneficial inhibitory effect on HCC development, particularly in 
patients with diabetes or cirrhosis, who are at high risk for HCC. 
The use of contrast enhanced ultrasound (CEUS) for the diagnosis of HCC in cirrhosis 
was questioned for the risk of false positive diagnosis in case of cholangiocarcinoma. 
The American College of Radiology has recently released a scheme called CEUS-
Liver Imaging Reporting And Data System (CEUS LI-RADS®), classifying lesions at 
risk for HCC investigated by CEUS. In this scheme, the expected diagnostic pattern of 
HCC, termed LR-5, corresponds to arterial phase hyperenhancement (rim or globular 
excluded) followed by late (≥60 seconds) and mild degree of washout. Although of 
great potential interest, the CEUS LI-RADS proposal has not yet been validated so far. 
This is why Terzi et al. aimed to validate CEUS LI-RADS® scheme for the diagnosis 
of HCC. A total of 1006 nodules in 848 patients with chronic liver disease at risk for 
HCC collected in 5 Italian centers were retrospectively analyzed. They show that the 
CEUS LI-RADS® class LR-5 is highly specific for HCC, enabling its use for a 
confident noninvasive diagnosis. 
 
